首页
登录
职称英语
Questions 27-33Reading Passage 3 has seven paragraphs A-G.From the list of hea
Questions 27-33Reading Passage 3 has seven paragraphs A-G.From the list of hea
游客
2024-01-09
56
管理
问题
Questions 27-33
Reading Passage 3 has seven paragraphs A-G.
From the list of headings below choose the most suitable heading for each paragraph.
Write the appropriate numbers (Ⅰ-Ⅹ) in boxes 27-33 on your answer sheet.
List of headings
Ⅰ The long-term impact
Ⅱ Acelebrated achievement
Ⅲ Early brilliance passes unrecognised
Ⅳ Outdated methods retain popularity
Ⅴ The basis of a new design is born
Ⅵ Frustration at never getting the design right
Ⅶ Further refinements meet persistent objections
Ⅷ Different in all respects
Ⅸ Bridge-maders look elsewhere
Ⅹ Transport developments spark a major change
[br] *
选项
答案
Ⅲ
解析
His first masterpiece ... gained little favourable publicity ... on the contrary ..
转载请注明原文地址:http://tihaiku.com/zcyy/3347603.html
相关试题推荐
Themostobjectionablepassagesinthenovelwere______attheinsistenceofthe
Philosophicalproblemsarisewhenpeopleaskquestionsthat,thoughvery____,h
Thispassageisadaptedfrommaterialpublishedin1993
PART1Theexaminerwillaskyousomequestionsaboutyourself,suchas:
PART1Theexaminerwillaskyousomequestionsaboutyourself,suchas:
PART1Theexaminerwillaskyousomequestionsaboutyourself,suchas:—Whatco
PART1Theexaminerwillaskyousomequestionsaboutyourself,suchas:—Whatco
PART1Theexaminerwillaskyouquestionsaboutyourself,suchas:——What’syo
PART1Theexaminerwillaskyouquestionsaboutyourself,suchas:—What’syo
PART1Theexaminerwillaskyouquestionsaboutyourself,suchas:—What’syo
随机试题
Forthispart,youareallowed30minutestowriteashortessayonthesmar
Nodirectrelationshiphasbeenprovenbetweenhighcholesterollevelsandheart
患者,男,35岁。尿频,尿道灼痛,会阴部隐痛1周。前列腺液镜检:白细胞增多,卵磷
用玉米的花药进行组织培养,单倍体幼苗期经秋水仙素处理后形成二倍体植株(该过程不考
上肢锥体束征是指A.Babinski(巴彬斯基征) B.Oppenheim(奥
对于慢性癌痛治疗,推荐选择的药物是A.氯丙嗪B.抗惊厥类药物C.三环类抗抑郁药D
文旅地产从字面上是“文化+旅游+地产”,但其本质和核心是“文旅”而非“地产”。文
世界500强企业关于优秀员工的12条核心标准:第一条,一个人的工作是他生存的基本
激励一词的含义的关键因素包括( )。A.物质要求 B.需要 C.努力 D
治疗香豆素类药过量引起的出血宜选用A.鱼精蛋白 B.维生素K C.维生素C
最新回复
(
0
)